Filing Flows › CytomX Therapeutics (CTMX) › R&D spending
CytomX Therapeutics (CTMX) R&D spending by quarter
CytomX Therapeutics' R&D spending was $16.5M in Q3 2026 (third quarter 2026), -6% from Q2 2026. Over the last 7 quarters it ranged from $13.3M (Q2 2025) to $21.2M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $16.5M | -6% | +8% |
| Q2 2026 | $17.6M | -9% | +32% |
| Q1 2026 | $19.2M | -9% | +2% |
| Q4 2025 | $21.2M | +39% | — |
| Q3 2025 | $15.3M | +15% | — |
| Q2 2025 | $13.3M | -29% | — |
| Q1 2025 | $18.9M | — | — |
Q3 2026 at a glance
CytomX Therapeutics, Q3 2026: revenue $1.7M (-72% year over year), net loss $20.0M, operating cash flow $16.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is CytomX Therapeutics' R&D spending?
CytomX Therapeutics' R&D spending was $16.5M in Q3 2026 (third quarter 2026), -6% from Q2 2026.
How has CytomX Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $13.3M (Q2 2025) to $21.2M (Q4 2025).